Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer
Xavier Pivot, Mark Pegram, Javier Cortes, Diana Lüftner, Gary Lyman, Giuseppe Curigliano, Igor Bondarenko, Ye Yoon, Younsoo Kim, Chul Kim (2019) Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer Eur J Cancer (IF: 7.1) 120 1-9Links
http://www.ncbi.nlm.nih.gov/pubmed/31445454http://dx.doi.org/10.1016/j.ejca.2019.07.015
Similar articles
Tools
Download Stork Mobile App
